Stimuliver receives DKK 2.4m in grant funding from Innovation Fund Denmark
2023
Stimuliver announces a further DKK 2.4m (approx. €320k) in grant funding to support company development and preclinical testing
Danish Innovation Fund Denmark awards Stimuliver further Innobooster funding
Stimuliver welcomes further funding to expand R&D team and preclinical studies
Copenhagen, Denmark, 2023 – Stimuliver ApS is an emerging biotech company developing a first-in-class vascularised tissue implant to treat acute and chronic liver diseases. Today announces further funding from the Danish Innovation Fund. This follows previous investment from BioInnovation Institute, Denmark's Export and Investment Fund, and Old College Capital.
Stimuliver is developing a treatment which aims to implant human liver tissue under the skin, providing host liver support to patients with failing livers and chronic metabolic diseases. The company was founded in Denmark by David Hay and Dagmara Szkolnicka and is a spinout from the University of Edinburgh.
The scalable liver implant technology developed at Stimuliver differentiates liver tissue from pluripotent stem cells and is not dependent on donor organ availability. Additionally, implants show favourable immunogenicity in immunocompetent animals as well as vascularization to the host system within few days. This may in the future provide a treatment which is available without waiting time and has the potential to reverse liver disease and prevent hospitalisations.
Stimuliver is incubated at the BioInnovation Institute in Copenhagen.
David Hay, co-founder and CEO said: “We are delighted to receive further Innobooster funding from the Danish Innovation Fund. The award will be used to expand our R&D team and support our extensive preclinical testing programmes, vital to the development of implantable human liver tissue for the clinic”
For more information please contact:
Stimuliver
David Hay, CEO
dave@stimuliver.bio
NOTES TO EDITORS
About Stimuliver
Stimuliver is a Danish biotech company with technology from the University of Edinburgh, established to develop a scalable, safe and effective treatment for diseases affecting the liver. The company’s first-in-class, vascularised and immunomodulatory liver tissue implant, aims to treat both acute and chronic liver diseases for which there are limited, and no treatment options currently available. www.stimuliver.bio
Innovation Fund Denmark
Innovation Fund Denmark invests in entrepreneurs, researchers and businesses that create value for Denmark and new solutions to our society’s biggest challenges - and supports the development of new knowledge and technology creating growth and employment in Denmark